RxDoctor Payments Data

Crystal Proud

Neurology with Special Qualifications in Child Neurology · Norfolk, VANPI 1013159177

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $663,626 of the $1,001,986 with a category attached, or 66.2%. Sarepta Therapeutics, Inc. accounts for 61.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $279,590, 3.3 times the $85,861 reported in 2019. Among neurology with special qualifications in child neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,001,986in general payments, 2019–2025

Across 854 payments — averaging $1173.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$613K
  • Biogen$263K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$68K
  • F. Hoffmann-la Roche AG$22K
  • Genentech USA, Inc.$10K
  • Hoffmann-la Roche Limited$10K
  • plus $17K from 12 others
$6,126,419in research payments, 2019–2025

Across 1,475 payments — averaging $4153.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sarepta Therapeutics, Inc.$3.9M
  • Novartis$724K
  • Biogen$626K
  • CSL Behring$445K
  • PTC Therapeutics, Inc.$101K
  • Vertex$96K
  • plus $275K from 8 others

What the payments were for

  • Consulting fees$663,62666%
  • Speaking & faculty fees$226,93223%
  • Travel & lodging$78,8998%
  • Food & beverage$24,0752%
  • Education$8,4541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001,986 in reported general payments places this provider in the 95th percentile of 23 neurology with special qualifications in child neurology providers in Virginia.

See all neurology with special qualifications in child neurology providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam11$289,640
Fluoxetine Hcl13$126
Prednisone13$68
Baclofen12$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$9,805$289,64011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 neurology with special qualifications in child neurology providers in Virginia.

Other neurology with special qualifications in child neurology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →